CONMED Corporation (CNMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.51B
Last updated: Nov 17, 2026 at 11:04 AM ET
CONMED Corporation (CNMD) Financials: Revenue, Profit and Cash Flow
CONMED reported revenue of $1.37B for the fiscal year ended Dec 31, 2025, up 5.2% from the year before. That year, net income was $47.05M with a net margin of 3.4%, operating cash flow was $170.69M and free cash flow was $150.88M. The quarter ended Sep 30, 2026 had revenue of $335.56M and net income of $19.80M.
Revenue and Margins
The operating margin was 7.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $763.52M, a compound annual rate of 6.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.37B | +5.2% | 54.6% | 7.5% | 3.4% |
| Dec 2024 | $1.31B | +5.0% | 56.1% | 15.3% | 10.1% |
| Dec 2023 | $1.24B | +19.1% | 54.3% | 9.7% | 5.2% |
| Dec 2022 | $1.05B | +3.4% | 54.6% | 6.7% | -7.7% |
| Dec 2021 | $1.01B | +17.2% | 56.2% | 10.9% | 6.2% |
| Dec 2020 | $862.46M | -9.7% | 53.4% | 5.3% | 1.1% |
| Dec 2019 | $955.10M | +11.1% | 54.9% | 8.3% | 3.0% |
| Dec 2018 | $859.63M | +7.9% | 54.6% | 8.3% | 4.8% |
| Dec 2017 | $796.39M | +4.3% | 54.1% | 5.9% | 7.0% |
| Dec 2016 | $763.52M | N/A | 53.5% | 4.9% | 1.9% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 64.5% from the year before. In the quarter ended Sep 2026, net income rose 592.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B | $862.46M | $955.10M | $859.63M | $796.39M | $763.52M |
| Cost of revenue | $624.25M | $573.98M | $568.50M | $474.23M | $442.60M | $402.16M | $430.38M | $390.52M | $365.35M | $355.19M |
| Gross profit | $750.48M | $733.03M | $676.25M | $571.25M | $568.04M | $460.30M | $524.72M | $469.11M | $431.04M | $408.33M |
| Research and development | $55.88M | $54.43M | $52.60M | $47.15M | $43.56M | $40.47M | $45.46M | $42.19M | $32.31M | $32.25M |
| Operating income | $102.62M | $200.33M | $120.60M | $70.05M | $109.72M | $46.01M | $79.11M | $71.31M | $46.94M | $37.68M |
| Net income | $47.05M | $132.42M | $64.46M | -$80.58M | $62.54M | $9.52M | $28.62M | $40.85M | $55.49M | $14.66M |
| EBITDA | $182.13M | $277.88M | $198.53M | N/A | $193.28M | $131.69M | $158.00M | $133.11M | $105.48M | $90.04M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $335.56M | $343.49M | $317.05M | $373.20M | $337.93M | $342.35M | $321.26M | $345.94M | $316.70M | $332.10M | $312.27M | $327.05M |
| Gross profit | $189.15M | $197.46M | $183.45M | $218.28M | $166.12M | $188.32M | $177.75M | $198.34M | $179.00M | $183.73M | $171.97M | $182.18M |
| Operating income | $37.14M | $36.41M | $25.41M | $36.62M | $11.88M | $38.16M | $15.96M | $52.50M | $65.71M | $47.11M | $35.01M | $50.19M |
| Net income | $19.80M | $23.07M | $13.83M | $16.74M | $2.86M | $21.42M | $6.04M | $33.75M | $48.98M | $29.98M | $19.71M | $33.07M |
Balance Sheet
As of Dec 2025, total debt of $834.94M exceeded cash and equivalents by $794.13M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.33B | $2.31B | $2.30B | $2.30B | $1.77B | $1.75B | $1.78B | $1.37B | $1.36B | $1.33B |
| Current assets | $672.86M | $640.01M | $615.65M | $581.23M | $460.12M | $416.65M | $397.36M | $374.35M | $356.78M | $330.51M |
| Cash and equivalents | $40.82M | $24.46M | $24.30M | $28.94M | $20.85M | $27.36M | $25.86M | $17.51M | $32.62M | $27.43M |
| Total liabilities | $1.29B | $1.34B | $1.47B | $1.55B | $980.58M | $1.04B | $1.06B | $706.87M | $726.53M | $748.41M |
| Short-term debt | $712.00K | $715.00K | $708.00K | $69.75M | $12.25M | $18.41M | $13.60M | $18.34M | $14.70M | $10.20M |
| Long-term debt | $834.23M | $905.07M | $973.14M | $985.08M | $672.41M | $735.22M | $755.21M | $438.56M | $471.74M | $488.29M |
| Shareholder equity | $1.03B | $962.68M | $834.22M | $745.54M | $785.43M | $709.04M | $710.47M | $662.27M | $631.43M | $580.58M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.30B | $2.30B | $2.31B | $2.33B | $2.32B | $2.33B | $2.30B | $2.31B | $2.32B | $2.29B | $2.31B | $2.30B |
| Total liabilities | $1.24B | $1.26B | $1.30B | $1.29B | $1.31B | $1.33B | $1.32B | $1.34B | $1.38B | $1.40B | $1.45B | $1.47B |
| Cash and equivalents | $47.97M | $37.33M | $35.03M | $40.82M | $38.93M | $33.94M | $35.48M | $24.46M | $38.47M | $28.87M | $33.85M | $24.30M |
| Shareholder equity | $1.06B | $1.04B | $1.02B | $1.03B | $1.01B | $1.00B | $977.64M | $962.68M | $932.90M | $881.83M | $854.66M | $834.22M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 88.4% of operating cash flow. Dividends came to 16.4% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $170.69M | $166.97M | $125.35M | $33.37M | $111.77M | $64.53M | $95.13M | $74.70M | $65.57M | $39.88M |
| Capital expenditures | $19.81M | $13.08M | $19.03M | $21.79M | $14.87M | $13.01M | $20.07M | $16.51M | $12.84M | $14.75M |
| Free cash flow | $150.88M | $153.88M | $106.32M | $11.58M | $96.90M | $51.52M | $75.07M | $58.19M | $52.72M | $25.13M |
| Dividends paid | $24.75M | $24.65M | $24.50M | $23.96M | $23.26M | $22.82M | $22.60M | $22.44M | $22.31M | $22.21M |
| Share repurchases | N/A | N/A | N/A | $69.53M | $0 | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | -$20.96M | -$13.08M | -$20.03M | -$249.53M | -$14.87M | -$13.64M | -$387.66M | -$16.51M | -$29.05M | -$266.02M |
| Financing cash flow | -$135.82M | -$151.00M | -$110.43M | $225.00M | -$101.55M | -$52.06M | $300.88M | -$72.27M | -$34.88M | $182.54M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $49.41M | $37.09M | $13.47M | $46.34M | $53.69M | $29.13M | $41.53M | $43.34M | $51.20M | $43.31M | $29.12M | $56.40M |
| Capital expenditures | $2.68M | $2.93M | $2.89M | $5.11M | $5.19M | $5.73M | $3.78M | $4.04M | $3.42M | $3.59M | $2.04M | $4.86M |
| Free cash flow | $46.73M | $34.16M | $10.58M | $41.22M | $48.50M | $23.41M | $37.76M | $39.30M | $47.78M | $39.72M | $27.09M | $51.54M |
Frequently Asked Questions About CNMD
What is CONMED's annual revenue?
CONMED reported revenue of $1.37B for the fiscal year ended Dec 31, 2025.
How fast is CONMED's revenue growing?
Revenue was up 5.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 9.6%.
Is CONMED profitable?
Yes. CONMED reported net income of $47.05M for the fiscal year ended Dec 31, 2025, with a net margin of 3.4%.
How much free cash flow does CNMD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $170.69M minus capital expenditures of $19.81M produced free cash flow of $150.88M.
How much debt does CONMED have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $834.23M, short-term debt of $712.00K and cash and equivalents of $40.82M.
CNMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts